This invention relates generally to wound dressings and, in particular, to vented wound dressings that provide a unique combination of a hydrogel and an anti-thrombogenetic layer to form effective patches for emergency situations, including battlefield applications.
There are instances when an emergency wound dressing may be required not only to stop bleeding, but also to vent the transfer of gasses and/or liquids from the wound. Bullet wounds in battlefield situations represent one such need. Until now, however, there are few if any bandages that will remain affixed to a recipient given heat and moisture from weather, sweating, and so forth.
This invention is a wound dressing that uses a novel combination of materials to provide a tenacious occlusive seal, even in the presence of excessive blood or heavy perspiration. The preferred embodiment combines an adhesive backing layer with a hydrogel layer providing superior hydrophilic gel adhesion. The product performs under extreme temperatures (i.e., 32-140° F.), and may be used to hold other dressings in place. The preferred embodiments may be entirely translucent, and include a large pull-tab for easy removal from a release layer. One or two dressings may be packaged in a pliable re-sealable protective pouch.
Different “vented” embodiments are disclosed. Preferred structures include a cover layer peripherally bonded to backing and hydrogel layers having a central aperture therethrough. The cover layer has one or more vent passages, and pressure is released through the central aperture and out these vent paths.
In preferred embodiments, layers that come in contact with blood products are preferably anti-thrombogenic to reduce or eliminate thrombi, or clotting that might interfere or obstruct the venting process. In particular, a blood-contacting cover and/or backing layers may use a thermoplastic polyurethane (TPU) film, more particularly a polyether TPU film.
This invention is a wound dressing that uses a novel combination of materials to provide a tenacious occlusive seal, even in the presence of excessive blood or heavy perspiration.
The hydrogel pad 102 may be obtained from Katecho, Inc. of Des Moines, Iowa (product code KM-10T). The backing material 110 is a polyester release liner (i.e., 3.0 mil), available from 3M Corp. of St. Paul, Minn., with a silicone coating on one side. Other vendors for the various materials are also possible. The structure further includes a clear, embossed tape medical tape piece 107 with a permanent adhesive, such as 3M 1527, bonded to a pull-tab 108, facilitating removal of the dressing from backing sheet 110.
The backing layer 104 may have a patient-facing adhesive layer, and the peripheral edge 106 of the backing layer may extend beyond the peripheral edge of the hydrogel pad 102 to expose this adhesive layer. Alternatively, backing layer 104 may not include an adhesive, in which case the peripheral edges of the backing layer 104 and the hydrogel pad 102 may be co-extensive. The release liner 110, however, preferaly extends beyond all sides of the backing layer 104, as shown in
In terms of dimensions, the dressing has a preferred width on the order of 3 to 6 inches and a preferred length on the order of 4 to 8 inches. Other shapes besides ovals may be used, including circles, squares and rectangles. Materials other than polyethylene may be used for the backing layer 104 so long as the adhesive and combined system is sufficiently tenacious in terms of adherence to the skin.
On occasion, the wound dressing may need to vent pressure built up from a chest cavity, for example, and expell gasses or liquids, including blood products. To address this, one or more vents such as 204 may be provided as shown in
As a further alternative, a passive or active status sensor may be used to indicate a user condition or to show that pressure release has occurred. As shown in
In the embodiment of
An adhesive-free release tab 608, uded to remove the dressing from release liner 601, may be provided by adhering a tape piece 606 to the tab 608. The adhesive-free release tab 608 may be printed (607) with product information. The release liner may be a polyester (i.e., 3.0 mil) film. A set of applicable dimensions for the vented product are provided in
Continuing the reference to
On the outer side of the backing layer, facing away from the recipient, there is attached a cover layer 614 having one or more vent holes 616, 618. The cover 614 is peripherally bonded to the outer surface of the backing layer using a ring-shaped polyester tape 620 having an adhesive on both sides. The cover 614 may also be attached directly to the backing layer with or without an adhesive, using thermal welding, for example.
As yet a further embodiment, as opposed to an open central aperture through the hydrogel and backing layers leading to a pocket formed with the cover layer, a one-way bicuspid 1102 or tricuspid valve of the type shown in
In all embodiments of this invention, layers that come in contact with blood products are preferably anti-thrombogenic to reduce or eliminate thrombi, or clotting. Thus, in embodiments that include a cover layer, such as layer 614 in
Thrombogenicity refers to the tendency of a material in contact with the blood to produce a thrombus, or clot. The term not only refers to fixed thrombi but also to emboli, thrombi that have become detached and travel through the bloodstream. Embodiments of this invention incorporate anti-thrombogenic blood-contacting layers because coagulation and thrombosis caused by platelet adhesion and activation on material surfaces may lead to functional failure and even fatal outcomes.
Blood-contacting cover and cover/backing layers may use a thermoplastic polyurethane (TPU) film, more particularly a polyether TPU film. More specifically, a product such as WPF 24-025 ABC may be used, a 2.5-mil polyether polyurethane film available from BASF, Inc. that exhibits anti-thrombogenic properties. It is believed that the anti-thrombogenic properties of such polyether TPU films are directly correlated to the MVTR (moisture vapor transmission rate) of the TPU chemistry—a higher MVTR results in higher anti-thrombogenicity.
This application is a Continuation-In-Part of U.S. patent application Ser. No. 16/144,170, filed Sep. 27, 2018, which is a Re-Issue application Ser. No. 14/247,884, which is a Continuation-In-Part of U.S. patent application Ser. No. 12/748,008, filed Mar. 26, 2010, which claims priority from U.S. Provisional Patent Application Ser. No. 61/163,613, filed Mar. 26, 2009, the entire content of each application being incorporated herein by reference.
Number | Date | Country | |
---|---|---|---|
61915198 | Dec 2013 | US | |
61163613 | Mar 2009 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16144170 | Sep 2018 | US |
Child | 16424117 | US | |
Parent | 12748008 | Mar 2010 | US |
Child | 14247884 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14247884 | Apr 2014 | US |
Child | 16144170 | US |